Novartis opens up a path of research to protect proteins that guard against cancer.

Novartis teams test combinations of targeted therapeutic agents to combat drug resistance in tumors.

Novartis collaborates with Homology Medicines to adapt and refine genome editing technology.

Novartis collaborates with the Banner Alzheimer’s Institute to test treatments for preventing Alzheimer’s disease.

Novel PRC2 inhibitor changes the expression of hundreds of genes in lab model

A Cell & Gene production unit staffed by a highly trained team at Novartis will soon begin operating in Stein, Switzerland.

Research exploring the first visible changes in the brain is helping scientists evaluate new potential treatments for Alzheimer’s.

Industry labs find that, contrary to earlier evidence, KRAS-driven tumors are not addicted to autophagy.

An immunologist shares tips from a team-based environment